Short-Term Mortality Risk in Dementia Patients Initiating Opioids: A Retrospective Cohort Study Comparing New Users and Consistent Users

Yeon Mi Hwang[1], Jennifer M. Hah[2], Tina Hernandez-Boussard[1]

[1] Center for Biomedical Informatics Research, School of Medicine, Stanford University, Stanford, CA, USA

[2] Department of Anesthesiology, Perioperative and Pain Medicine, School of Medicine, Stanford University, Stanford, CA, USA

Corresponding Author:
Yeon Mi Hwang, PhD
Center for Biomedical Informatics Research
Stanford University
3180 Porter Drive
Stanford, CA, 94305
ymh@stanford.edu

Abstract

Importance: The opioid epidemic continues to grow, and while the adverse effects of opioids are well-known, their impact on short-term mortality in patients with dementia or mild cognitive impairment (MCI) remains understudied, despite the high vulnerability of this population.

Objective: To evaluate the short-term mortality risk associated with initiating opioids in patients diagnosed with dementia or MCI

Design: Retrospective observational cohort study

Setting: Multisite healthcare system in Northern California

Participants: Health records of 27,759 patients aged 50–100 with dementia or MCI, with encounters between January 1, 2015, and July 31, 2024. Exclusions included patients who died within 14 days of surgery, had fewer than three clinical encounters before and after diagnosis, or were first diagnosed with dementia/MCI at death.

Exposures: Initial opioid use following dementia or MCI onset. Patients were categorized as new users (no opioid use in the prior year) or consistent users (prior opioid exposure).

Main Outcome and Measures: Short-term mortality risk, defined as death within 14 days of first opioid exposure, with additional monitoring up to 60 days after opioid initiation. Hazard ratios were calculated using Cox proportional hazards regression, adjusting for demographics, comorbidities, and medication exposure. We used GPT.3.5-Turbo to identify possible causes of death from unstructured clinical documentation, supplemented by data from California public death records.

Results: Among 14,107 patients prescribed opioids following the onset of dementia/MCI onset, 9444 were new users and 4663 were consistent users. The cohort was predominantly female (56.0%), with a median age of 81 years (IQR:73–87). New users exhibited a 1.95-fold (95% CI, 1.55–2.46; P < 0.0001) increased risk of mortality within 14 days of initial opioid exposure compared to consistent users. Respiratory illnesses were more prevalent among new users who died within 14 days after opioid exposure (62% vs. 48%, P<0.1), particularly pneumonia (38% vs. 19%, P<0.01).

Conclusion: Opioid initiation in patients with dementia or MCI is linked to significantly higher short-term mortality, particularly in those with respiratory conditions. These findings highlight the need for cautious prescribing and close monitoring, given the increased mortality risk.

Introduction

Pain is a common experience among patients with dementia ,[1–3] partly due to age-related comorbidities including arthritis, fractures, and other chronic conditions.[4–6] However, managing pain in this population is challenging because cognitive impairment can interfere with accurate pain assessment.[2] Opioids, while commonly prescribed for moderate to severe pain, carry substantial risks for the elderly population,[7] including respiratory depression, falls, sedation, and confusion. These risks are particularly concerning at the start of therapy.[8–10] For dementia patients, who may struggle to effectively communicate pain symptoms, the potential for adverse outcomes may be even greater.[2]

Given the vulnerability of patients with comorbid dementia and chronic pain, multiple studies have examined the impact of opioid use in this group. Taipale et al.[11] found that the new opioid users faced an elevated risk of hip fracture, reporting an adjusted hazard ratio (aHR) of 1.96 (95% Confidence Interval [1.27-3.02]) during the first two months of use. Similarly, Hamina et al.[12] observed a greater risk of hospital-treated pneumonia among dementia patients who initiated opioids. More recently, Jensen-Dahm et al.[13] conducted a Danish cohort study in 2023 and reported a significantly higher mortality risk for opioid-exposed patients with dementia., with an aHR of 4.13 [3.98–4.30] within 180 days of opioid initiation compared to opioid-naive patients. The highest risk was noted in the initial 14 days, showing an aHR of 10.95 [9.87–12.15].

The objective of this study was to assess the impact of opioid initiation on short-term mortality by comparing those who began opioids after dementia onset with those who had opioid exposure within the year preceding their diagnosis. We distinguished between opioid-naive patients and those with prior exposure among opioid-exposed patients in order to minimize the confounding by indication, as opioids are frequently prescribed for patients with underlying comorbidities. Additionally, we utilized a large language model (LLM) to analyze unstructured clinical notes, allowing for a more nuanced understanding of health conditions at the time of death.

Method

Study setting and study population

This is a multi-site retrospective cohort study at Stanford Health Care Alliance (SHA) from 2015/01/01 to 2024/07/31. SHA is an integrated health system that comprises three sites (academic, community hospital, and community practice network). The study was approved by the Stanford University Institutional Review Board (Protocol 47644). Informed consent was waived under exemption 4: research on existing data.

Cohort selection is described in Figure 1. We conducted a retrospective cohort study of individuals who had any encounters at SHA between January 1, 2015, and July 31,

2024 (n = 3,247,002). From this source population, we identified individuals with at least one diagnosis of dementia or mild cognitive impairment (MCI) (n = 32,460). We included MCI due to potential overlap with early-stage dementia. We limited the cohort to individuals aged 50 to 100 at the time of their first diagnosis (n = 31,252). We additionally excluded individuals who did not survive beyond 14 days post-surgery (n = 31,187). This was done to avoid confounding effects from surgical mortality, as opioids are commonly administered during or after surgery. Ensuring continuity of care, we included only individuals with at least three encounters both before and after their first dementia diagnosis (n = 28,021). Finally, to further ensure continuity of care and exclude individuals who were diagnosed dementia/MCI for the first time at the time of death, we limited the cohort to those who survived more than 7 days after their initial dementia/MCI diagnosis (n = 27,759).

Measures

Outcome

Our primary outcome was short-term mortality, defined as death within 14 days after the first opioid exposure; we also monitored mortality up to 60 and 180 days. Death dates were obtained from the SHA electronic health record (EHR) and California's Public Use Death File.[14] The EHR data provides a rich longitudinal health profile from both structured data and unstructured clinical notes. However, mortality studies relying solely on EHR data may overlook deaths occurring outside of the healthcare system. To address this limitation, we incorporated statewide death records to more accurately capture out-of-hospital deaths. While deaths among patients residing outside California may be missed, we anticipate minimal impact on our findings since our cohort was limited to elders receiving continuity of care.

Exposure

Our exposure of interest was the initiation of opioid use following the onset of dementia or MCI (Figure 1). In order to avoid confounding by indication, we distinguished patients who were new users and consistent users of opioid and compared these two groups. The exposure group (new users) comprised individuals who were prescribed opioids after the onset of dementia or MCI, with no opioid use in the preceding year. The reference group (consistent users) included individuals with opioid use within one year before their initial dementia or MCI diagnosis and continued opioid use. The opioid medications included in the study were buprenorphine, codeine, fentanyl, hydrocodone, hydromorphone, meperidine, methadone, morphine, oxycodone, and tramadol (Figure 1, Table S1, and Table S2).

Covariates

We collected patient characteristics and health conditions from EHR prior to the first opioid exposure following the initial diagnosis of dementia or MCI. Patient

characteristics included age at diagnosis, race, ethnicity, body mass index (BMI), insurance status, comorbidities, and medication exposures. Variables are defined in Table S3.

We focused on comorbid conditions known to be associated with dementia and mortality, recorded within two years before the first opioid exposure. We included comorbidities in these categories: cardiovascular and vascular diseases, respiratory and pulmonary diseases, metabolic and endocrine disorders, liver and renal diseases, cancer and immune system conditions, neurological and cognitive conditions, mental health conditions, and other conditions such as excessive alcohol use and hearing loss. Table S4 provides a complete list of comorbid conditions and their ICD codes.

For medication exposures, we examined drugs taken within one year before the first opioid exposure. We collected exposure status on medications associated with dementia—such as anti-dementia drugs[15] and those that could pose harmful side effects for older adults based on the American Geriatrics Society's (AGS) Beers Criteria.[16] Additionally, we included clinician-recommended (JMH) dementia-relevant medications. The complete list of individual medications and their RxNorm codes is provided in Table S5. For analysis, we grouped medications into therapeutic or chemical subcategories as shown in Table S5.

Analyses

Descriptive analysis

We examined the distribution of covariates between new users and consistent users. Categorical variables were compared using the chi-squared test. Continuous variables were evaluated using Welch's t-test. Benjamini-Hochberg method was used to correct for multiple testing errors. All analyses were conducted using the PyPI package tableone (v.0.9.1).[17] Variables that contained cells with fewer than 20 cases were dropped to protect patient privacy. We also conducted descriptive analysis between opioid-exposed and unexposed patients.

Statistical analysis

We employed a Cox proportional hazards model to compute hazard ratios (HR) for 14-day short-term mortality using PyPI package lifelines (v 0.29.0).[18] Mortality was monitored up to 60 days to determine when the 95% confidence intervals for the survival probabilities of new users and consistent opioid users overlapped. To further characterize the survival patterns of the exposure groups, we additionally monitored survival up to 180 days. Model performance was assessed using the Concordance Index. To explore the time-varying effects of the exposure, we employed Aalen's

additive hazards model. Missing values were imputed using the median. Variables with less than 300 cases were excluded from the analysis to avoid sparse data issues and ensure sufficient statistical power. We did not monitor survival beyond 60 days because we assumed the impact of opioid initiation does not persist over extended periods and the survival model on longer follow-up time could be confounded by other impacts such as exposure to additional medications and disease progression and subject to an increasing number of competing risks. We also utilized a random survival forest model to evaluate feature importance.

We conducted several additional analyses. First, we performed a subgroup analysis by categorizing opioid exposures into strong and weak opioids[19]. Second, we conducted separate analyses on subsamples of individuals with dementia and those with MCI to determine if the effects differed between these groups. The dementia and MCI groups are not mutually exclusive, as individuals were included in a group if they had at least one diagnosis of the corresponding condition.

For our sensitivity analyses, we explored multiple scenarios to assess the robustness of our findings. First, we compared first-time opioid users with individuals who had been using opioids consistently for at least 90 days during the pre-diagnosis observation period (long-term consistent users). Second, we analyzed the subset of patients diagnosed with pneumonia within 7 days before their first opioid exposure to assess the impact of pre-existing pneumonia. Finally, we assessed the hazard of subsequent pneumonia development between new users and consistent users among individuals without prior pneumonia to investigate whether opioid initiation increased the risk of developing pneumonia. We assumed that the proportional hazards assumption was valid for our study's short follow-up period but tested this assumption using generalized linear regression of Schoenfeld residuals against time and the Kolmogorov-type supremum test. Variables that violated this assumption were adjusted in the sensitivity analysis.

Identification of potential reasons for short-term mortality

After identifying patients who died within 14 days of their first opioid exposure following dementia/MCI onset, we identified mentions of death in their clinical notes within three days of the date of death. These notes were securely processed using Generative Pre-training Transformer-3.5 (GPT 3.5) Turbo to identify the top three potential health conditions contributing to each patient's death (Table S6).[20] This was done to uncover clinical correlations difficult to detect in structured data alone.

To assess the reliability of these GPT outputs, we randomly sampled 50 notes and checked hallucination errors, verifying whether the identified conditions aligned with documented causes of death or primary health concerns. Additionally, we sampled another 50 notes that explicitly specified a principal diagnosis at the time of death and compared these diagnoses to the GPT responses. Some notes were not death summary notes and did not contain detailed information on causes of death or primary health issues. Given our exploratory approach to identifying broad patterns in potential

causes of death, we did not assess each response for clinical accuracy. We then utilized GPT-4o to categorize each condition into predefined health condition categories, assigning conditions to multiple categories if applicable. A clinician (JMH) reviewed the cause-category mappings to ensure accuracy, and adjustments were made based on their feedback.

Result

Cohort description

The cohort is described in Table 1, Table S7, and Table S8. Of 27,759 individuals diagnosed with dementia/MCI, 14,107 (50.8%) were exposed to opioids after their diagnosis (opioid-exposed). Of them, 4663 patients had opioid exposure in the year preceding their initial dementia/MCI diagnosis (consistent users), while 9444 initiated opioid prescriptions post-diagnosis (new users; Figure 1). The opioid-exposed cohort was predominantly female (56.0%), White/Caucasian (64.2%), non-Hispanic/Latino (88.0%), insured by Medicaid/Medicare (53.3%), and had normal BMI (42.0%). The median age was 81 years (IQR: 73–87). Mortality rates following initial opioid exposure were 4.0% at 14 days, 91.1% at 60 days, and 14.2% at 180 days.

Compared to consistent users, new users were older (P<0.001), had a higher proportion of Asian patients and a lower proportion of Black patients (P<0.001), fewer Latino/Hispanic individuals (P<0.001), and a lower prevalence of obesity (P<0.001). In terms of cognitive impairment severity, new users had a lower prevalence of MCI and a higher prevalence of dementia (P<0.001). Additionally, consistent users had more comorbidities across 30 of 34 conditions and elevated exposure rates to 43 of the 45 medications (P<0.05). Furthermore, new users experienced higher mortality at 14, 60, and 180 days compared to consistent users (4.8% vs. 2.6%, P<0.001; 9.3% vs. 8.1%, P<0.05; 14.6% vs. 13.3%, P<0.05; Table 1).

Survival analysis

New users demonstrated significantly higher mortality risk within 14 days of initial opioid exposure (aHR 1.95 [1.55-2.46]; P<0.0001; Figure 2). This model's concordance index was 0.79. In the extended 60-day follow-up analysis, the 95% confidence intervals of survival curves began to overlap at day 51, with progressive convergence over time (concordance index 0.75; Figure 3). The extended 180-day follow-up analysis showed that the slopes of both survival curves remained similar after day 51 and up to 180 days (concordance index 0.73; Figure S1). The cumulative hazard coefficient from the Aalen additive hazards model began to plateau at day 42 (Figure S2). However, the Aalen model's concordance index was 0.49.

Subgroup analysis by opioid strength showed that new users of strong opioids had significantly higher mortality risk (aHR 2.07 [1.57-2.72], P<0.0001; Figure S3). In

contrast, weak opioid exposure showed no significant association with survival rates (aHR 1.80 [0.64-5.05], P = 0.26; Figure S3). Among patients diagnosed with MCI, the association was not significant (aHR 1.22 [0.74-2.03], P = 0.44; Figure S4). However, in patients with dementia, the mortality risk was significantly elevated (aHR 2.16 [1.68-2.78], P<0.0001; Figure S4). A sensitivity analysis comparing the treatment group to long-term consistent users (≥90 days of pre-diagnosis opioid exposure) confirmed the robust association between opioid initiation and short-term mortality (aHR 1.84 [1.28-2.65], P<0.001; Figure S5). Additional sensitivity analysis adjusting for variables that violated the proportional hazards assumption (diagnosis of delirium, hyperlipidemia, schizophrenia/non-mood psychotic disorder, exposure to acetaminophen, benzodiazepine, insulin, anesthetic, warfarin, and white race) demonstrated minimal impact on our main findings (aHR 2.02, 95% CI 1.59-2.58; Figure S6).

Identification of potential causes for short-term mortality

Within 14 days of their initial opioid exposure, 450 new users and 121 consistent users died (Table 1). We collected and processed 438 notes for 179 patients in the new users and 138 notes for 62 patients in the consistent users. In a random sample of 50 notes, no hallucinations were detected. In a random sample of 50 notes specifying a principal diagnosis at the time of death, we identified four mismatches with the GPT responses (Table S9). However, three of these mismatched responses were still mapped to the same category as the specified principal diagnosis. One was partially matched. Figure 4 shows that respiratory-related conditions exhibited the largest difference in prevalence between the groups, occurring in 62% of new users compared to 48% of consistent users (P<0.1). A more detailed breakdown of respiratory issues revealed that respiratory failure was the most common condition in both groups. However, pneumonia-related conditions were particularly high among new users, with a 19% higher prevalence (P<0.05, Figure 4).

In a sensitivity analysis examining short-term mortality in patients with underlying pneumonia, the aHR rose to 2.38 [1.45, 3.91] (P<0.01, Figure S7). In contrast, among individuals without preexisting pneumonia, opioid initiation was not associated with the risk of developing pneumonia (aHR = 1.00 [0.73,1.38], P=0.98; Figure S7).

Discussion

In this multisite study, newly prescribed opioids after dementia onset were associated with a 1.95-fold increased risk of mortality within 14 days compared to pre-existing opioid use. This heightened risk persisted for 51 days after initiation. Among new users who died within the first 14 days, respiratory complications, particularly pneumonia,

were the predominant cause of death. Moreover, both opioid strength and cognitive impairment severity showed positive associations with short-term mortality risk.

Our study is the first to examine short-term mortality by directly comparing patients who initiated opioids after dementia onset with those who had prior opioid exposure. Recent research from Denmark reported elevated mortality rates among opioid-exposed patients with dementia, but that study compared opioid-exposed versus unexposed patients using a one-year washout period before dementia diagnosis.[13] Our study aimed to reduce confounding by indication by including patients with prior opioid exposure in our reference group, focusing specifically on those who began opioid use after dementia onset. In our study, patients with pre-existing opioid use even had higher rates of comorbid conditions and higher prescription rates for other medications affecting health outcomes.

We found a 1.95-fold increased mortality risk among new users, particularly among patients prescribed stronger opioids and those with dementia. The influence of opioid strength on this association aligns with previous findings that found correlations between opioid strength and side effects, such as respiratory depression, falls, nausea, and gastrointestinal problems.[11,21–26] Prior research highlights increased mortality risk associated with new prescription opioid use compared to non-users for noncancer pain, particularly among patients prescribed stronger opioids, but details of comorbid diagnoses further increasing mortality risk remain limited. [27] There is a paucity of research assessing the association between the severity of cognitive impairment and the risk of opioid-related side effects. One possible explanation is that severe cognitive impairment can hinder the ability to communicate discomfort or early signs of adverse effects, leading to delayed recognition and management of opioid-related adverse effects.

After 51 days, the mortality risk associated with opioid initiation began to converge between new and consistent users. While previous studies have demonstrated elevated risks of opioid-related adverse effects during the initial phase of treatment in elderly populations,[11,13,28] these comparisons were between opioid-exposed and unexposed patients and lacked a specific timeframe. Our study took a novel approach by comparing new users to consistent users within the exposed group, identifying a specific 51-day window of heightened risk, and offering clinicians with an actionable timeframe for intervention. This 51-day period highlights a critical time frame for closely monitoring patients who newly initiated opioid therapy. Potential risk reduction strategies may include weekly follow-up for opioid-related adverse events and increased patient and caregiver education regarding opioid-related adverse effect monitoring. Additionally, we included cumulative coefficients from Aalen's additive model to assess the time-varying impact on mortality over this 60-day period. However, it is important to interpret Aalen's additive model result as supplementary, given the model's relatively low concordance index.

Preexisting pneumonia emerged as a significant factor in the association between short-term mortality and opioid initiation, especially among new users who died within the first 14 days. We found a particularly high prevalence of pneumonia among new

users as a potential cause of early mortality, based on GPT-extracted causes of death. This prompted us to investigate whether the association reflected pneumonia resulting from opioid exposure, as suggested by previous studies,[12,28,29] or preexisting conditions. To differentiate between short-term mortality linked to preexisting pneumonia (diagnosed within 7 days before opioid initiation) and newly acquired pneumonia, we conducted sensitivity analyses. Among patients with preexisting pneumonia, we observed a HR increase of up to 2.38 fold for short-term mortality associated with opioid initiation. Whereas, patients without pre-existing pneumonia showed no significant association between opioid initiation and subsequent pneumonia development. One possible explanation is that the increased risk of respiratory depression could potentially exacerbate outcomes for patients already experiencing pneumonia in dementia patients, given the correlation between opioid initiation and an elevated risk of respiratory depression.[10,25,30] **Future research examining non-opioid pain management for patients with comorbid dementia and pneumonia diagnoses to reduce acute mortality risk is warranted.**

To minimize confounding by indication, we examined patients with prior opioid exposure before dementia diagnosis as the reference group. Since opioids are typically prescribed for acute post-surgical pain or for moderate to severe pain associated with comorbidities, this approach helps to clarify the mortality risk linked to initiating opioids in patients with dementia. As expected, we observed a higher prevalence rate of comorbidities and a greater rate of medication prescription among consistent opioid users.

This study should be interpreted within the context of several limitations. First, this was a single health system study in Northern California, which limits generalizability to other populations across the United States, although our system comprises an academic hospital, a community hospital, and a community practice network. Another limitation of this study is its small sample size. A larger cohort would allow for drug-specific analyses and a more thorough investigation into the role of pneumonia in the association between short-term mortality and opioid initiation. Future studies can address the limitations of sample size and generalizability by validating findings in larger and more diverse populations. Furthermore, while we obtained death dates for patients who passed away outside our center, we lacked access to their clinical notes at the time of death, which restricted our understanding of their health status during this period. Access to these notes could reveal additional health patterns that are not captured in our current data.

Conclusion

In conclusion, this study highlights a significantly elevated short-term mortality risk associated with initiating opioid use in patients with dementia, particularly within the first 14 days following exposure. The findings underscore the importance of close monitoring and proactive management strategies during this critical period. Additionally, our

integration of EHR data with public death records, alongside the application of LLMs to unstructured notes, provided a richer, more nuanced understanding of the clinical context surrounding opioid initiation and mortality in this population. Patients who initiate opioid therapy after a dementia diagnosis have an elevated risk of death within the first 14 days of exposure, with this risk persisting through day 51. This period provides clinicians with a crucial window for close monitoring of patients beginning opioid treatment.

		Missing	Overall (n=14,107)	new user (n=9444)	consistent user (n=4663)	P
Dementia category						
Mild cognitive impairment, n (%)			5213 (37.0)	3182 (33.7)	2031 (43.6)	<0.001
Alzheimer's disease, n (%)			3160 (22.4)	2411 (25.5)	749 (16.1)	<0.001
Vascular dementia, n (%)			1319 (9.3)	881 (9.3)	438 (9.4)	0.93
Other/Unspecified dementia, n (%)			10637 (75.4)	7390 (78.3)	3247 (69.6)	<0.001
Patient characteristics						
Sex	**Female**	1	7904 (56.0)	5292 (56.0)	2612 (56.0)	1.000
	Male		6202 (44.0)	4152 (44.0)	2050 (44.0)	
Age at diagnosis, median [Q1,Q3]		0	81.0 [73.0,87.0]	81.0 [74.0,87.0]	79.0 [71.0,86.0]	<0.001
Age group, n (%)	**50-59**	0	695 (4.9)	398 (4.2)	297 (6.4)	<0.001
	60-69		1720 (12.2)	986 (10.4)	734 (15.7)	
	70-79		4080 (28.9)	2643 (28.0)	1437 (30.8)	
	80-89		5499 (39.0)	3856 (40.8)	1643 (35.2)	
	90-100		2113 (15.0)	1561 (16.5)	552 (11.8)	
Race, n (%)	**White**	57	9021 (64.2)	6007 (63.8)	3014 (65.0)	<0.001
	Asian		2019 (14.4)	1433 (15.2)	586 (12.6)	
	Black		725 (5.2)	422 (4.5)	303 (6.5)	
	Native American/Hawaiian/Pacific Islander		117 (0.8)	73 (0.8)	44 (0.9)	
	Unknown/Refused		265 (1.9)	209 (2.2)	56 (1.2)	
	Other		1903 (13.5)	1266 (13.5)	637 (13.7)	
Ethnicity, n (%)	**Hispanic/Latino**	13	1326 (9.4)	835 (8.9)	491 (10.5)	<0.001
	Non-Hispanic/Non-Latino		12402 (88.0)	8326 (88.2)	4076 (87.5)	
	Unknown/Refused		366 (2.6)	274 (2.9)	92 (2.0)	

Insurance, n (%)	Medicare/Medicaid	226	7402 (53.3)	4932 (53.2)	2470 (53.6)	0.78
	Private		4481 (32.3)	3013 (32.5)	1468 (31.9)	
	Other		1998 (14.4)	1332 (14.4)	666 (14.5)	
BMI, median [Q1,Q3]		914	25.4 [22.3,28.9]	25.1 [22.1,28.6]	25.8 [22.6,29.6]	<0.001
BMI category, n (%)	Underweight	1158	624 (4.8)	426 (5.0)	198 (4.5)	<0.001
	Normal weight		5436 (42.0)	3717 (43.5)	1719 (39.1)	
	Overweight		4451 (34.4)	2913 (34.1)	1538 (34.9)	
	Obese		1812 (14.0)	1127 (13.2)	685 (15.6)	
	Severely obese		626 (4.8)	365 (4.3)	261 (5.9)	
Death outcome						
death, n (%)		0	6104 (43.3)	4140 (43.8)	1964 (42.1)	0.06
Days to death from first opioid exposure, mean (SD)		8004	837.4 (910.6)	837.7 (913.9)	836.8 (904.0)	0.97
Death within 14 days after first opioid exposure, n (%)		0	572 (4.1)	451 (4.8)	121 (2.6)	<0.001
Death within 60 days after first opioid exposure, n (%)		0	1261 (8.9)	882 (9.3)	379 (8.1)	0.02
Death within 180 days after first opioid exposure, n (%)		0	1997 (14.2)	1379 (14.6)	618 (13.3)	0.03

Table 1 Descriptive statistics of the study cohort

Categorical variables were compared using the chi-squared test. Continuous variables were evaluated using Welch's t-test. The Benjamini-Hochberg method was used to correct for multiple testing errors. All analyses were conducted using the PyPI package tableone (v.0.9.1)[17]. Variables that contained cells with fewer than 20 cases were dropped to protect patient privacy. Variables are defined in Table S3.

Figure 1 Flowchart of cohort and exposure group selection

Descriptive statistics of the dementia/MCI cohort comparing opioid-exposed and unexposed groups are presented in Table S8. Descriptive statistics of the opioid-exposed cohort comparing new users and consistent users are presented in Table 1 and Table S7.

Figure 2: 14-day survival probability curve comparing new users and consistent users

New users (n=9444) had a lower likelihood of survival during the 14-day follow-up period, with an adjusted hazard ratio (aHR) of 1.95 (95% CI: [1.55, 2.47]). The model achieved a concordance index of 0.79, indicating good predictive performance. Hazard ratios were computed using a Cox proportional hazards model, adjusted for age at diagnosis, race, ethnicity, body mass index (BMI), insurance status, comorbidities, and medication exposures. Complete lists of comorbidities and medications can be found in Tables S4 and S5. Variables with fewer than 300 cases were excluded from the analysis. Significance levels: +: P < 0.1, *: P < 0.05, **: P < 0.01, ***: P < 0.001, ****: P < 0.0001.

Figure 3: 60-day survival probability curve comparing new users and consistent users

The 95% confidence interval of 60-day survival probability curves comparing new users and consistent users overlapped at day 51. New users (n=9444) had a higher adjusted hazard ratio (aHR) for 60-day survival post-opioid initiation, with an aHR of 1.44 (95% CI: [1.25, 1.67], P<0.0001). The model achieved a concordance index of 0.74, indicating good predictive performance. Although the survival curves for new and consistent users started to overlap at day 51, the aHR for new users remained higher due to substantial differences in survival during the early phase of the follow-up period. Hazard ratios were computed using a Cox proportional hazards model, adjusted for age at diagnosis, race, ethnicity, body mass index (BMI), insurance status, comorbidities, and medication exposures. Complete lists of comorbidities and medications are available in Tables S4 and S5. Variables with fewer than 300 cases were excluded from the analysis. Significance levels: +: P < 0.1, *: P < 0.05, **: P < 0.01, ***: P < 0.001, ****: P < 0.0001.

A

Prevalence of GPT-Extracted Potential Causes of Death Among Patients with Short-Term Mortality

B

Figure 4: Bar plot of prevalence rate difference in GPT-extracted potential causes of death between new and consistent users

Plot A shows the difference in prevalence rates of GPT-extracted potential causes of death between new and consistent users, shown as a bar plot. Plot B shows the difference in prevalence rate focusing on specific respiratory-related conditions. We collected clinical notes mentioning death among individuals who passed away within 14 days after opioid initiation (438 notes for 179 patients in new users and 138 notes for 62 patients in consistent users). These notes were processed through secure GPT-3.5 Turbo to identify potential causes of death. The prompt used for this analysis is provided in Table S6. Among 50 randomly selected notes, no instances of hallucination were detected. If a note did not contain information about the health condition at the time of death, GPT-3.5 Turbo outputted 'NA'. When a primary cause of death was specified, it was listed as the first cause; if unspecified, GPT-3.5 Turbo identified the primary health concern mentioned in the note at the time of death. We utilized GPT-4o to categorize these potential causes into predefined health condition categories. If a cause fit into multiple categories, it was assigned to all relevant categories. A clinician (JMH) reviewed the cause-category mappings to ensure accuracy, and adjustments were made based on their feedback. Significance levels: +: P < 0.1, *: P < 0.05, **: P < 0.01, ***: P < 0.001, ****: P < 0.0001.

Disclosure

Contributors

Yeon Mi Hwang: Conceptualization, Resources, Data Curation, Software, Formal Analysis, Investigation, Visualization, Data Interpretation, Methodology, Writing - original draft, Writing - review and editing; Jennifer M. Hah: Conceptualization, Methodology, Data Interpretation, Writing - review and editing; Tina Hernandez-Boussard: Conceptualization, Supervision, Writing - review and editing, Administrative, technical, or material support; YH and T-HB had full access to the data in the study and verified the data.

Funding Statement

This project was supported by grant number R01HS024096 from the Agency for Healthcare Research and Quality. The content is solely the responsibility of the authors and does not necessarily represent the official views of the Agency for Healthcare Research and Quality.

Data Sharing Statement

All clinical logic has been shared. Results have been aggregated and reported within this paper to the extent possible while maintaining privacy from personal health information as required by law.

Declaration of Interests

YH, JMH, and TH-B declare no conflict of interest.

References

1. Barry HE, Parsons C, Passmore AP, Hughes CM. Exploring the prevalence of and factors associated with pain: a cross-sectional study of community-dwelling people with dementia. *Health Soc Care Community*. 2016;24(3):270-282. doi:10.1111/hsc.12204

2. Corbett A, Husebo B, Malcangio M, et al. Assessment and treatment of pain in people with dementia. *Nat Rev Neurol*. 2012;8(5):264-274. doi:10.1038/nrneurol.2012.53

3. Achterberg W, Lautenbacher S, Husebo B, Erdal A, Herr K. Pain in dementia. *Pain Rep*. 2020;5(1):e803. doi:10.1097/PR9.0000000000000803

4. Bunn F, Burn AM, Goodman C, et al. Comorbidity and dementia: a scoping review of the literature. *BMC Med*. 2014;12(1):192. doi:10.1186/s12916-014-0192-4

5. Shega J, Emanuel L, Vargish L, et al. Pain in persons with dementia: complex, common, and challenging. *J Pain*. 2007;8(5):373-378. doi:10.1016/j.jpain.2007.03.003

6. Fox C, Smith T, Maidment I, et al. The importance of detecting and managing comorbidities in people with dementia? *Age Ageing*. 2014;43(6):741-743. doi:10.1093/ageing/afu101

7. Kim JY, Kim JH, Yee J, Song SJ, Gwak HS. Risk factors of opioid-induced adverse reactions in elderly male outpatients of Korea Veterans Hospital. *BMC Geriatr*. 2018;18(1):293. doi:10.1186/s12877-018-0990-1

8. Prostran M, Vujović KS, Vučković S, et al. Pharmacotherapy of pain in the older population: The place of opioids. *Front Aging Neurosci*. 2016;8:144. doi:10.3389/fnagi.2016.00144

9. Dowell D, Ragan KR, Jones CM, Baldwin GT, Chou R. CDC clinical practice guideline for Prescribing Opioids for pain - United States, 2022. *MMWR Recomm Rep*. 2022;71(3):1-95. doi:10.15585/mmwr.rr7103a1

10. Babu KM, Brent J, Juurlink DN. Prevention of opioid overdose. *N Engl J Med*. 2019;380(23):2246-2255. doi:10.1056/NEJMra1807054

11. Taipale H, Hamina A, Karttunen N, et al. Incident opioid use and risk of hip fracture among persons with Alzheimer disease: a nationwide matched cohort study: a nationwide matched cohort study. *Pain*. 2019;160(2):417-423. doi:10.1097/j.pain.0000000000001412

12. Hamina A, Taipale H, Karttunen N, et al. Hospital-Treated Pneumonia Associated with Opioid Use Among Community Dwellers with Alzheimer's Disease. *JAD*.

2019;69(3):807-816. doi:10.3233/JAD-181295

13. Jensen-Dahm C, Janbek J, Gasse C, Laursen TM, Waldemar G. Excessive mortality risk associated with new opioid use in older people with dementia. *Alzheimers Dement*. 2023;19(S22):e077103. doi:10.1002/alz.077103

14. California Department of Public Health, Center for Health Statistics and Informatics, Vital Statistics Branch. Statewide Death Profile. Published online September 2024. Accessed October 2024. https://www.cdph.ca.gov/Programs/CHSI/Pages/Data-and-Statistics-.aspx

15. Frederiksen KS, Waldemar G, eds. *Management of Patients with Dementia: The Role of the Physician*. 1st ed. Springer Nature; 2021. doi:10.1007/978-3-030-77904-7

16. By the 2023 American Geriatrics Society Beers Criteria® Update Expert Panel. American Geriatrics Society 2023 updated AGS Beers Criteria® for potentially inappropriate medication use in older adults. *J Am Geriatr Soc*. 2023;71(7):2052-2081. doi:10.1111/jgs.18372

17. Pollard TJ, Johnson AEW, Raffa JD, Mark RG. tableone: An open source Python package for producing summary statistics for research papers. *JAMIA Open*. 2018;1(1):26-31. doi:10.1093/jamiaopen/ooy012

18. Davidson-Pilon C. *Lifelines, Survival Analysis in Python*. Zenodo; 2024. doi:10.5281/ZENODO.12549337

19. *WHO Guidelines for the Pharmacological and Radiotherapeutic Management of Cancer Pain in Adults and Adolescents*. World Health Organization; 2018. Accessed October 27, 2024. https://www.ncbi.nlm.nih.gov/books/NBK537492/

20. Ng MY, Helzer J, Pfeffer MA, Seto T, Hernandez-Boussard T. Development of secure infrastructure for advancing generative AI research in healthcare at an academic medical center. *Res Sq*. Published online September 24, 2024. doi:10.21203/rs.3.rs-5095287/v1

21. Rowbotham MC, Twilling L, Davies PS, Reisner L, Taylor K, Mohr D. Oral opioid therapy for chronic peripheral and central neuropathic pain. *N Engl J Med*. 2003;348(13):1223-1232. doi:10.1056/NEJMoa021420

22. Daoust R, Paquet J, Cournoyer A, et al. Side effects from opioids used for acute pain after emergency department discharge. *Am J Emerg Med*. 2020;38(4):695-701. doi:10.1016/j.ajem.2019.06.001

23. Seppala LJ, Petrovic M, Ryg J, et al. STOPPFall (Screening Tool of Older Persons Prescriptions in older adults with high fall risk): a Delphi study by the EuGMS Task and Finish Group on Fall-Risk-Increasing Drugs. *Age Ageing*. 2021;50(4):1189-1199. doi:10.1093/ageing/afaa249

24. Santosa KB, Lai YL, Brummett CM, et al. Higher amounts of opioids filled after surgery increase risk of serious falls and fall-related injuries among older adults. *J Gen Intern Med*. 2020;35(10):2917-2924. doi:10.1007/s11606-020-06015-6

25. Fox LM, Hoffman RS, Vlahov D, Manini AF. Risk factors for severe respiratory depression from prescription opioid overdose. *Addiction*. 2018;113(1):59-66. doi:10.1111/add.13925

26. Rekatsina M, Paladini A, Viswanath O, et al. Opioids in the elderly patients with cognitive impairment: A narrative review. *Pain Ther*. 2022;11(2):381-394. doi:10.1007/s40122-022-00376-y

27. Jani M, Girard N, Bates DW, Buckeridge DL, Dixon WG, Tamblyn R. Comparative risk of mortality in new users of prescription opioids for noncancer pain: results from the International Pharmacosurveillance Study. *Pain*. Published online October 29, 2024:10.1097/j.pain.0000000000003446. doi:10.1097/j.pain.0000000000003446

28. Vozoris NT, Wang X, Fischer HD, et al. Incident opioid drug use and adverse respiratory outcomes among older adults with COPD. *Eur Respir J*. 2016;48(3):683-693. doi:10.1183/13993003.01967-2015

29. Edelman EJ, Gordon KS, Crothers K, et al. Association of prescribed opioids with increased risk of community-acquired pneumonia among patients with and without HIV. *JAMA Intern Med*. 2019;179(3):297-304. doi:10.1001/jamainternmed.2018.6101

30. Boom M, Niesters M, Sarton E, Aarts L, Smith TW, Dahan A. Non-analgesic effects of opioids: opioid-induced respiratory depression. *Curr Pharm Des*. 2012;18(37):5994-6004. doi:10.2174/138161212803582469